Orgenesis Inc
NASDAQ:ORGS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Nissan Motor Co Ltd
XHAM:NISA
|
JP |
|
A
|
AGCO Corp
XBER:AGJ
|
US |
Orgenesis Inc
Other Items
Orgenesis Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Orgenesis Inc
NASDAQ:ORGS
|
Other Items
$628k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
51%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Items
-$5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
32%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Items
-$4.2B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
21%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Items
-$85m
|
CAGR 3-Years
74%
|
CAGR 5-Years
55%
|
CAGR 10-Years
33%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Items
-$507.8m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Items
$584.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Orgenesis Inc
Glance View
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. The company is headquartered in Germantown, Maryland and currently employs 151 full-time employees. The company went IPO on 2010-07-01. The firm is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The company has developed a Point of Care Platform (POCare Platform) comprised of three enabling components, which includes a pipeline of POCare advanced therapies that are designed to be processed and produced, automated closed POCare technology systems, and a worldwide network of POCare research institutes and hospitals (POCare Network). Its products in clinical use include KYSLECEL, Tissue Genesis Icellator for Cell Assisted Lipotransfer, Cartil-S Autologous products for the treatment of osteoarthritis, and Chondroseal Autologous products for the treatment of cartilage defects.
See Also
What is Orgenesis Inc's Other Items?
Other Items
628k
USD
Based on the financial report for Dec 31, 2024, Orgenesis Inc's Other Items amounts to 628k USD.
What is Orgenesis Inc's Other Items growth rate?
Other Items CAGR 10Y
51%
